CD300LD Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell pool derived from the A-549 lung adenocarcinoma epithelial cell line. This product features targeted disruption of the CD300LD gene, encoding an inhibitory immunoreceptor that downregulates myeloid cell activation and inflammatory responses. The polyclonal mixture offers a robust loss-of-function model without clonal constraints, suitable for population-level analyses. CRISPR/Cas9-mediated gene disruption ensures reliable inactivation, facilitating investigations into CD300LD-dependent signaling pathways.
The A-549 cell line is a well-characterized model of human lung adenocarcinoma, originating from alveolar type II epithelial cells. A-549 exhibits an adherent epithelial morphology and is extensively used to study non-small cell lung cancer, respiratory epithelium function, and drug responses. Its stable karyotype and ease of genetic manipulation make it an ideal host for knockout studies. This background provides a physiologically relevant context for examining CD300LD in lung adenocarcinoma, particularly in signaling networks that may influence tumor progression and immune modulation.
CD300LD is an ITIM-containing inhibitory immunoreceptor that, upon engagement by ligands such as phosphatidylserine, recruits the phosphatases SHP-1 and SHP-2. This recruitment dephosphorylates downstream signaling molecules, thereby suppressing NF-??B activation and reducing production of pro-inflammatory cytokines, including TNF-??. Interferon-gamma upregulates CD300LD expression, modulating the inhibitory threshold. The CD300LD/SHP-1/SHP-2 axis constitutes a critical negative regulatory node in immunoreceptor signaling and cytokine regulation pathways. Disruption of CD300LD lifts this inhibition, potentially leading to enhanced NF-??B-driven responses.
In A-549 cells, CD300LD knockout allows dissection of this immunoreceptor??s role in non-immune epithelial cells, where it may contribute to cancer immune evasion and microenvironment modulation. Lung adenocarcinoma cells can exploit CD300LD-mediated inhibitory pathways to dampen inflammatory signals, and loss of CD300LD may alter cytokine profiles and NF-??B activity. This model enables study of cell-autonomous CD300LD functions without immune cell crosstalk, clarifying its contribution to lung cancer pathobiology and its potential as a therapeutic target.
This knockout cell pool supports diverse research applications, including immune checkpoint-like signaling in non-immune cells, lung cancer biology, and immunomodulatory pathways. Standard assays such as western blotting, RT-qPCR, ELISA for cytokines, NF-??B reporter assays, and flow cytometry are suitable for characterizing CD300LD-dependent effects. These polyclonal cells enable investigations into autoimmune mechanisms, tumor immune evasion, and inflammatory disorders, serving as a valuable tool for mechanistic and drug discovery studies. For further inquiries, please contact Ascent Research.
